HSV1 Oncolysis-Immune Checkpoint Inhibition Therapy for Breast Cancer Meningeal Metastases

Abstract

Meningeal metastasis is a terminal disease classified under stage IV breast cancer which affects 10-15% of patients. Currently there is no cure limiting survival to less than 4months. The research conducted during this period explored a novel treatment approach which had hitherto not been investigated for breast cancer meningeal metastases that of combination therapy with oncolytic HSV1 and immune checkpoint inhibition. Based on our initial investigation, the combination treatment approach was therapeutic for breast cancer meningeal metastases in our murine model. The tumor growth was inhibited following combination therapy survival was prolonged together with a remarkable recovery of neurological symptoms. Cancer-immune pathways regulated during combination therapy for this disease were identified for further investigation.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2021
Accession Number
AD1146194

Entities

People

  • Kumudu D. Kuruppu

Organizations

  • Massachusetts General Hospital

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Body Weight
  • Breast Cancer
  • Cancer
  • Combination Therapy
  • Covid-19
  • Data Analysis
  • Diseases And Disorders
  • Health Services
  • Inhibition
  • Magnetic Resonance
  • Medical Personnel
  • Neoplasms
  • Oncolytic Viruses
  • Research Facilities
  • Therapy
  • Viruses

Fields of Study

  • Biology
  • Medicine

Readers

  • Neurotrauma and Rehabilitation Medicine.
  • Oncology (Cancer Research).